Ligand Pharmaceuticals Incorporated has grown revenue 17% a year over three years and 4.1% a year over five, with earnings per share compounding at 80%. Revenue growth, 3-year annual rate: +17% (Biotechnology median +17%). Revenue growth, 5-year rate: +4.1%, growth has picked up over the last three years. Earnings per share, 3-year rate: +80%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 17, FY2009 to FY2025, as filed.

LGNDLigand Pharmaceuticals Incorporated

Healthcare

$301.78+81% 1Y

$301.78

$166.7652 weeks$316.44

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +55% year on year and operating margin widening (+49.1 points), but earnings down −333% year on year.

2 good, 1 to watch

Revenue trend+55% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +4% a year.

Earnings trend−333% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+49.1 points operating

Trailing-twelve-month operating margin, 29.5% now against -19.7% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbetter than 85% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is LGND growing?

Ligand Pharmaceuticals Incorporated has grown revenue 17% a year over three years and 4.1% a year over five, with earnings per share compounding at 80%.

+17%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +4.1%
Revenue growth, 5-year rate · +17% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +80%
Earnings per share, 3-year rate · revenue +17% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed